SYSTEMATIC REVIEW article
Front. Neurol.
Sec. Multiple Sclerosis and Neuroimmunology
Vitamin D Deficiency and Multiple Sclerosis Relapse: A Meta-Analysis
Provisionally accepted
- Beijing Fengtai Hospital of Integrated Traditional and Western Medicine, Beijing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: This meta-analysis was conducted to systematically evaluate the dose-response relationship between serum 25-hydroxyvitamin D [25(OH)D] levels and the annualized relapse rate (ARR) in multiple sclerosis (MS), and to investigate the effect of vitamin D supplementation on reducing relapse risk. Methods: Randomized controlled trials (RCTs) published from inception to April 2025 were retrieved from PubMed, Medline, Web of Science, Cochrane Library, and EMBASE. Study quality was assessed using the Cochrane RoB-2 tool. Meta-analyses were performed using RevMan 5.3. The primary outcome was ARR. Secondary outcomes included the Expanded Disability Status Scale (EDSS) score and serum 25(OH)D levels. Results: 9 studies comprising 1078 participants were included. No significant difference in EDSS scores was observed between the intervention and control groups (mean difference (MD)=-0.11, 95%CI [-0.40, 0.18], Z=0.73, P=0.47). Serum 25(OH)D levels were significantly higher in the intervention group (pooled MD=44.97, 95%CI [29.93, 60.01], Z=5.86, P<0.001). Subgroup analysis by vitamin D dosage showed that the low/medium-dose group significantly reduced ARR (pooled MD=-0.14, 95%CI [-0.26, -0.03], P=0.01), while the high-dose group had no significant effect on ARR (pooled MD=0.05, 95%CI [-0.08, 0.18], P=0.42). No significant overall difference in ARR was found between the two groups (pooled MD=-0.07, 95%CI [-0.18,0.03], Z=-1.37, P=0.17). Conclusion: The results of this meta-analysis showed that vitamin D supplementation, regardless of dosage, could significantly increase the serum 25(OH)D level in patients with multiple sclerosis. Subgroup analysis showed that low/medium-dose vitamin D supplementation could significantly reduce the ARR, while high-dose supplementation had no significant effect on ARR. There was no significant difference in EDSS scores between the experimental group and the control group.
Keywords: Meta-analysis, Multiple Sclerosis, Relapse rate, Systematic review, Vitamin D
Received: 18 Oct 2025; Accepted: 10 Dec 2025.
Copyright: © 2025 Zhang, Yu, Zu, Lv, Chen and Feng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xuedan Feng
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.